Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study
- PMID: 24344084
- PMCID: PMC3963836
- DOI: 10.1161/CIRCULATIONAHA.113.004050
Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study
Abstract
Background: Reduced low forced expiratory volume in 1 second (FEV1) is reportedly associated with an increased risk of atrial fibrillation (AF). Extant reports do not provide separate estimates for never smokers or for blacks, who incongruously have lower AF incidence than whites.
Methods and results: We examined 15 004 middle-aged blacks and whites enrolled in the Atherosclerosis Risk in Communities (ARIC) cohort study. Standardized spirometry data were collected at the baseline examination. Incident AF was identified from the first among the following: International Classification of Diseases codes for AF on hospital discharge records or death certificates or 12-lead ECGs performed during 3 triennial follow-up visits. Over an average follow-up of 17.5 years, a total of 1691 participants (11%) developed new-onset AF. The rate of incident AF was inversely associated with FEV1 in each of the 4 race and sex groups. After multivariable adjustment for traditional cardiovascular disease risk factors and height, hazard ratios of AF comparing the lowest with the highest quartile of FEV1 were 1.37 (95% confidence interval, 1.02-1.83) for white women, 1.49 (95% confidence interval, 1.16-1.91) for white men, 1.63 (95% confidence interval, 1.00-2.66) for black women, and 2.36 (95% confidence interval, 1.30-4.29) for black men. The above associations were observed across all smoking status categories. Moderate/severe airflow obstruction (FEV1/forced vital capacity <0.70 and FEV1 < 80% of predicted value) was also associated with higher AF incidence.
Conclusions: In this large population-based study with a long-term follow-up, reduced FEV1 and obstructive respiratory disease were associated with a higher AF incidence after adjustment for measured confounders.
Keywords: atrial fibrillation; forced expiratory volume; pulmonary disease, chronic obstructive; respiratory physiological phenomena; risk factors; vital capacity.
Conflict of interest statement
Figures
References
-
- Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C. Heart disease and stroke statistics—2010 update. Circulation. 2010;121:e46–e215. - PubMed
-
- Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The framingham heart study. Circulation. 1998;98:946–952. - PubMed
-
- Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The atherosclerosis risk in communities (aric) study. Circulation. 2011;123:1501–1508. - PMC - PubMed
-
- Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, Calkins H, Connolly SJ, Curtis AB, Darbar D, Ellinor PT, Go AS, Goldschlager NF, Heckbert SR, Jalife J, Kerr CR, Levy D, Lloyd-Jones DM, Massie BM, Nattel S, Olgin JE, Packer DL, Po SS, Tsang TS, Van Wagoner DR, Waldo AL, Wyse DG. Prevention of atrial fibrillation: Report from a national heart, lung, and blood institute workshop. Circulation. 2009;119:606–618. - PMC - PubMed
-
- Sin DD, Wu LL, Man S. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127:1952–1959. - PubMed
Publication types
MeSH terms
Grants and funding
- ZIA ES101574/ImNIH/Intramural NIH HHS/United States
- IRC1 HL099452-01/HL/NHLBI NIH HHS/United States
- N01-HC-55022/HC/NHLBI NIH HHS/United States
- ZIA ES025045/ImNIH/Intramural NIH HHS/United States
- R01 HL116900/HL/NHLBI NIH HHS/United States
- R21 HL109611/HL/NHLBI NIH HHS/United States
- T32-HL-007779/HL/NHLBI NIH HHS/United States
- N01-HC-55015/HC/NHLBI NIH HHS/United States
- T32HL007024/HL/NHLBI NIH HHS/United States
- N01-HC-55018/HC/NHLBI NIH HHS/United States
- HHSN268201100007C/HL/NHLBI NIH HHS/United States
- N01-HC-55016/HC/NHLBI NIH HHS/United States
- U01 HL096902/HL/NHLBI NIH HHS/United States
- T32 HL007024/HL/NHLBI NIH HHS/United States
- N01 HC055015/HL/NHLBI NIH HHS/United States
- ZIA ES049019/ImNIH/Intramural NIH HHS/United States
- RC1 HL099452/HL/NHLBI NIH HHS/United States
- L30 HL110223/HL/NHLBI NIH HHS/United States
- N01-HC-55021/HC/NHLBI NIH HHS/United States
- T32 HL007779/HL/NHLBI NIH HHS/United States
- N01 WH042117/WH/WHI NIH HHS/United States
- N01-HC-55019/HC/NHLBI NIH HHS/United States
- ZIA ES102385/ImNIH/Intramural NIH HHS/United States
- N01-HC-55020/HC/NHLBI NIH HHS/United States
- N01 HC055018/HL/NHLBI NIH HHS/United States
- K08 HS023683/HS/AHRQ HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
